Ngā hua rapu - Daniel Tenney

  • E whakaatu ana i te 1 - 1 hua o te 1
Whakamahine hua
  1. 1
    Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915

    Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915 mā James Larkin, Jeffrey Weber, Georgina V Long, Jonathan Baden, Hao Tang, Corey Ritchings, Michele Del Vecchio, Keyur Desai, Daniel Tenney, Han Chang, Gina Fusaro, David Balli, Sonia Dolfi, Sheen Wang, Shu-Pang Huang

    I whakaputaina 2025-07-01

    Purpose CheckMate 915 (NCT03068455) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that correlate with benefit from adjuvant immunotherapy.Patients and met...

    Whakaahuatanga katoa

    Whiwhi kuputuhi katoa
    Tuhinga

    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: